The purpose of this study is to determine whether giving abciximab (ReoPro) to children with sickle cell disease who are hospitalized for acute pain crisis will improve their pain and shorten the time spent in the hospital, when compared with standard supportive care.

Start Date01 Nov 2013

Sponsor / Collaborator

St. Louis University

NCT03087539 / Unknown statusPhase 2

Exploratory Phase II Clinical Trial to Evaluate the Efficacy and Safety of Clotinab® (Abciximab) in Acute Myocardial Infarction Patients: Multicenter, Randomized, Double Blind, Placebo-controlled and Parallel Group Trial

Exploratory Phase II Clinical Trial to Evaluate the Efficacy and Safety of Clotinab® (Abciximab) in Acute Myocardial Infarction Patients: Multicenter, Randomized, Double-Blind, Placebo-controlled and Parallel Group Trial

Start Date01 May 2013

Sponsor / Collaborator

ISU Abxis Co., Ltd.

NCT02105870 / Unknown statusNot ApplicableIIT

A Randomized Control Trial of Intracoronary Reopro to Improve Coronary Microvascular Function

Microvascular dysfunction is a key determinant of pathogenesis and outcome in patients suffering an acute myocardial infarction.
The investigators hypothesise that treatment with intracoronary abciximab, a potent anti platelet agent, at the time of coronary stent insertion, will improve microvascular function.

Start Date01 Feb 2012

Sponsor / Collaborator

University of Melbourne

100 Clinical Results associated with Abciximab

100 Translational Medicine associated with Abciximab

100 Patents (Medical) associated with Abciximab

2,344

Literatures (Medical) associated with Abciximab

27 Aug 2024·Blood Advances

An αIIbβ3 monoclonal antibody traps a semiextended conformation and allosterically inhibits large ligand binding

Article

Author: Wang, Lu ; Coller, Barry S ; Li, Jihong ; Wang, Jialing ; Walz, Thomas ; Coller, Barry S.

Abstract:

Monoclonal antibodies (mAbs) have provided valuable information regarding the structure and function of platelet αIIbβ3. Protein disulfide isomerase (PDI) has been implicated in αIIbβ3 activation and binds to thrombin-activated αIIbβ3. Using human platelets as the immunogen, we identified a new mAb (R21D10) that inhibits the binding of PDI to platelets activated with thrombin receptor–activating peptide (T6). R21D10 also partially inhibited T6-induced fibrinogen and PAC-1 binding to platelets, as well as T6- and adenosine 5'-diphosphate–induced platelet aggregation. Mutual competition experiments showed that R21D10 does not inhibit the binding of mAbs 10E5 (anti-αIIb cap domain) or 7E3 (anti-β3 β-I domain), and immunoblot studies indicated that R21D10 binds to β3. The dissociation of αIIbβ3 by EDTA had a minimal effect on R21D10 binding. Cryogenic electron microscopy of the αIIbβ3-R21D10 Fab complex revealed that R21D10 binds to the β3 integrin-epidermal growth factor 1 (I-EGF1) domain and traps an intermediate conformation of αIIbβ3 with semiextended leg domains. The binding of R21D10 produces a major structural change in the β3 I-EGF2 domain associated with a new interaction between the β3 I-EGF2 and αIIb thigh domains, which may prevent the swing-out motion of the β3 hybrid domain required for high-affinity ligand binding and protect αIIbβ3 from EDTA-induced dissociation. R21D10 partially reversed the ligand binding priming effect of eptifibatide, suggesting that it could convert the swung-out conformation into a semiextended conformation. We concluded that R21D10 inhibits ligand binding to αIIbβ3 via a unique allosteric mechanism, which may or may not be related to its inhibition of PDI binding.

01 Jun 2024·Journal of thrombosis and haemostasis : JTH

A novel technique to quantify the kinetics of blood clot contraction based on the expulsion of fluorescently labeled albumin into serum

Article

Author: Litvinov, Rustem I ; Weisel, John W ; Peshkova, Alina D

BACKGROUND:

The platelet-driven contraction or retraction of blood clots has been utilized to obtain blood serum for laboratory studies, but now, in vitro clot contraction assays are used in research laboratories and clinics to assess platelet functionality. The static final extent of clot contraction measured using a clot size or expelled serum volume can be supplemented substantially with a dynamic analysis.

OBJECTIVES:

To provide a step-by-step protocol for a relatively simple and affordable new automated methodology to follow the kinetics of blood clot contraction, which allows for simultaneous measurements of various samples at a time and requires only a fluorescence plate reader.

METHODS:

The kinetics of clot contraction in whole blood was assessed by continuously detecting the fluorescence intensity of fluorescein isothiocyanate-albumin added to a blood sample before clotting and expelled into the serum during clot shrinkage.

RESULTS:

The clots are formed and fluorescence is measured in the wells of a black multiwell plate using a standard plate fluorescent reader. The specificity of this technique for clot contraction has been demonstrated by the strong inhibitory effects of blebbistatin, latrunculin A, and abciximab. To validate the new technique, increased fluorescence intensity in the contracting clots was measured in parallel with a visual decrease in clot size performed with the same blood samples.

CONCLUSION:

The resulting clot contraction dynamics based on the expulsion of fluorescein isothiocyanate-albumin can be quantified using a number of kinetic parameters as well as a phase kinetics analysis. The advantages and drawbacks of the new technique are discussed.

15 May 2024·Cureus Journal of Medical Science

Role of Intracoronary Adrenaline in the Treatment of No-Reflow Phenomenon in Patients Undergoing Percutaneous Coronary Intervention

Article

Author: Simoni, Leonard ; Goda, Artan ; Ziu, Kristi ; Gjana, Armand ; Dibra, Alban

The no-reflow phenomenon is defined as the failure to restore coronary flow demonstrated by the reduced or missing flow in angiography despite the patent artery. There are pharmacological strategies proposed and studied to manage the no-reflow phenomenon. The medication groups used are purine nucleoside (adenosine), calcium channel blockers (verapamil, nicardipine), beta 2 receptor agonists (adrenaline, nitroprusside), fibrinolytic agents (streptokinase, tissue plasminogen activators), glycoprotein IIb/IIIa inhibitors (abciximab, tirofiban). We present a case of a woman hospitalized in non-ST elevation myocardial infarction (NSTEMI) conditions. The patient underwent coronary angiography, in which a single vessel coronary artery disease (CAD); left anterior descending (LAD) stenosis of 90% was found. In this condition, the patient underwent percutaneous coronary intervention (PCI) of LAD. The no-reflow phenomenon occurred with thrombolysis in myocardial infarction (TIMI) flow grade of 0 during the procedure. As a consequence, the patient presented chest pain and important hypotension (BP of 70/45). Because of the hypotensive state of the patient, we decided to administer intracoronary (IC) adrenaline directly. In our case, we used adrenaline as a first-line treatment for the no-flow phenomenon due to the hypotensive state during the PCI procedure. Generally, we initially use IC nitrate or IC adenosine to resolve the phenomenon, and when the no-reflow persists we use IC adrenaline because of its side effects mentioned above. Anyway, we believe that in specific cases of hypotension and bradycardia, the use of adrenaline as the first line of therapy should be considered.

News (Medical) associated with Abciximab

05 Dec 2022

·www.globenewswire.com

TFF Pharmaceuticals Announces Leadership Transition

Glenn Mattes to step down as Chief Executive Officer and as a Member of the Board of Directors Dr. Harlan F. Weisman, Vice Chairman of the Board, appointed as Interim Chief Executive Officer FORT WORTH, Texas, Dec. 05, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced that Glenn Mattes will step down as Chief Executive Officer and Member of the Board of Directors. Dr. Harlan F. Weisman, Vice Chairman of the Board, has been appointed Interim Chief Executive Officer, effective December 5, 2022. “On behalf of the entire Board of Directors and our shareholders, I would like to thank Glenn for his leadership and accomplishments,” said Dr. Aaron Fletcher, TFF Pharmaceuticals’ Chairman of the Board. “During Glenn’s tenure, TFF Pharmaceuticals completed its IPO financing, advanced two proprietary pipeline candidates into clinical testing, and began collaborations with many of the leading global biotechnology and pharmaceuticals companies. Under his leadership, Thin Film Freezing applications have expanded, and the platform is now recognized as a promising, next-generation technology in drug delivery. We thank Glenn for helping TFF Pharmaceuticals, and we wish him well in his future endeavors.” “I would like to thank the dedicated employees of TFF Pharmaceuticals for having the opportunity and privilege to work with all of you over the last five years on a truly unique and innovative technology that could have a great impact on many patients,” said Glenn Mattes. “I am confident that under Harlan’s leadership, this mission will continue, and I look forward to helping the Board in any way during this transition period for the Company.” “I am honored to serve as Interim Chief Executive Officer of TFF Pharmaceuticals, and I would like to thank our Board of Directors for this opportunity,” said Dr. Harlan F. Weisman. “Based upon the Company’s significant pipeline growth and impressive collaboration activity, I remain confident that we are only starting to realize the full therapeutic and commercial potential of Thin Film Freezing technology.” Harlan F. Weisman, M.D. has more than 30 years of experience as a senior healthcare executive responsible for the discovery, development, regulatory approval and launch of pharmaceutical, biopharmaceutical, medical device and diagnostic products. He is currently Managing Director of And-One Consulting, LLC, advising medical product companies, investment firms, and government and non-government healthcare organizations in formulating and implementing strategies for driving innovation in healthcare products and services. He is on advisory committees to the Johns Hopkins University Institute for Basic Biomedical Sciences and the Memorial Sloan Kettering Cancer Center Technology Development Fund. Dr. Weisman began his career in the pharmaceutical industry at Centocor, Inc., where he pioneered monoclonal antibodies as medical breakthroughs for wide therapeutic applications, including ReoPro®, REMICADE®, Simponi® and STELARA® which have combined annual sales of over $8 Billion. He was the head of R&D when Johnson & Johnson acquired Centocor in 1999. He then became President of J&J Pharmaceutical R&D, where he accelerated pipeline growth by advancing more than15 new molecular entities into late-stage development within 3 years, and gaining approvals of 10 drugs with over $15 Billion in annual sales. Dr. Weisman was promoted to Company Group Chairman, Pharmaceutical R&D, and had executive oversight of ALZA Corporation and J&J Pharmaceutical R&D, and led the acquisition and integration of 3-Dimensional Pharmaceuticals and later TransForm Pharmaceuticals. Dr. Weisman was Co-founder, Chairman and CEO of Flame Biosciences, a clinical stage company focused on the research, development, and commercialization of transformative therapies for cancer, from January 2020 to January 2022. Between December 2012 and December 2013, Dr. Weisman was Chairman and Chief Executive Officer of Coronado Biosciences, a biopharmaceutical company developing novel immunotherapies for autoimmune diseases and cancer. Dr. Weisman graduated from the University of Maryland with High Honors and the University of Maryland School of Medicine Cum Laude. After his residency in Internal Medicine at Mount Sinai Hospital in New York, he was a fellow in cardiovascular disease at Johns Hopkins Hospital, and was then appointed as Assistant Professor of Medicine at Johns Hopkins University School of Medicine, Consultant Cardiologist, Johns Hopkins Hospital, and Director of the Experimental Cardiac Pathology Laboratory. About TFF Pharmaceuticals’ Thin Film Freezing technology platformTFF Pharmaceuticals’ proprietary Thin Film Freezing (TFF) technology allows for the transformation of both existing compounds and new chemical entities into dry powder formulations exhibiting unique characteristics and benefits. The Thin Film Freezing process is a particle engineering process designed to generate dry powder particles with advantageous properties for inhalation, as well as parenteral, nasal, oral, topical and ocular routes of administration. The process can be used to engineer powders for direct delivery to the site of need, circumventing challenges of systemic administration and leading to improved bioavailability, faster onset of action, and improved safety and efficacy. The ability to deliver therapies directly to the target organ, such as the lung, allows TFF powders to be administered at lower doses compared to oral drugs, reducing unwanted toxicities and side effects. Laboratory data suggests the aerodynamic properties of the powders created by Thin Film Freezing can deliver as much as 75% of the dose to the deep lung. Thin Film Freezing does not introduce heat, shear stress, or other forces that can damage more complex therapeutic components, such as fragile biologics, and instead enables the reformulation of these materials into easily stored and temperature-stable dry powders, making therapeutics and vaccines more accessible for distribution worldwide. The advantages of Thin Film Freezing can be used to enhance traditional delivery or combined to enable next-generation pharmaceutical products. About TFF PharmaceuticalsTFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaging patented rapid freezing technology to develop and transform medicines into potent dry powder formulations for better efficacy, safety, and stability. The company’s versatile Thin Film Freezing (TFF) technology platform has broad applicability to convert most any drug, including vaccines, small and large molecules, and biologics, into an elegant dry powder highly advantageous for inhalation, with improved absorption so drugs can also be delivered to the eyes, nose and topically to the skin. TFF has two lead drug candidates in the clinic: Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder and continues to expand its pipeline by collaborating with a broad array of pharmaceutical companies, academic institutions, and government partners to revolutionize healthcare around the globe. The TFF Platform is protected by 120+ patents issued or pending in the U.S. and internationally. To learn more about TFF Pharmaceuticals and its product candidates, visit the Company’s website at https://tffpharma.com. Safe Harbor This press release contains forward-looking statements regarding TFF Pharmaceuticals, Inc., including, the benefits of the Company’s TFF platform and the Company’s plans to add to its existing pipeline of product candidates. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the Company may not be able to successfully conclude clinical testing or obtain pre-market approval of any of its dry powder product candidates, (ii) no drug product incorporating the TFF platform has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (iii) the Company has no current agreements or understandings with any large pharmaceutical companies for the development of a drug product incorporating the TFF Platform, (iv) the risk that the Company will not be able to conclude a long-term commercial agreement with any third-party, and (vi) those other risks disclosed in the section “Risk Factors” included in the Company’s Quarterly Report on Form 10-Q filed with the SEC on November 14, 2022. TFF Pharmaceuticals cautions readers not to place undue reliance on any forward-looking statements. TFF Pharmaceuticals does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law. TFF Contacts: Corporate Contact:Bill Begien VP of Investor Relations TFF Pharmaceuticals, Inc.c (617) 842-2222bbegien@tffpharma.com Investor Relations Contact:Corey Davis, Ph.D.LifeSci Advisors(212) 915-2577cdavis@lifesciadvisors.com Media Contact:Raena Mina, Ph.D.LifeSci Communicationsrmina@lifescicomms.com

Executive ChangeIPO

13 Jul 2022

·www.prnewswire.com

Four New Sets of Pre-Clinical Data Further Expands the Evidence Supporting Abelacimab

Additional Pharmacodynamic Data on Abelacimab Released at the 2022 Congress of the International Society on Thrombosis and Haemostasis (ISTH) CAMBRIDGE, Mass., July 13, 2022 /PRNewswire/ -- Anthos Therapeutics, a clinical-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, announced that four new research updates were presented on abelacimab during the Venous Thromboembolism poster session at the ongoing International Society on Thrombosis and Haemostasis 2022 Congress in London, UK. "Coagulation is a complex multilayered process and the potential benefits of inhibiting Factor XI are becoming increasingly clear. These preclinical studies add important information characterizing the pharmacodynamic effects of abelacimab and further extend our understanding of the biological effects of Factor XI inhibition," said Dan Bloomfield, Chief Medical Officer at Anthos Therapeutics. "With a growing body of evidence from ongoing studies both in the clinic and the lab, and a recent FDA Fast Track designation granted for abelacimab in thrombosis associated with cancer, we are becoming increasingly confident about the potential of our novel dual-acting Factor XI/XIa inhibitor may offer in the future as a treatment advance." The details of each poster presentation are provided below: PB0927 - Abelacimab does not influence the effects of two commonly used antiplatelet agents in vitro This study investigated the effects of clinically relevant doses of abelacimab on the inhibition of platelet aggregation by commonly used antiplatelet agents, aspirin and ticagrelor, in vitro. It demonstrated that abelacimab did not affect the level of antiplatelet inhibition achieved either by aspirin or ticagrelor confirming that abelacimab will not interfere with the benefits of these antiplatelet agents. PB0925 - Abelacimab has no effect on platelet aggregation induced by TRAP-6 and collagen FXI has been identified as a ligand to platelet receptors ApoER2 and GPIbα on the surface of stimulated platelets. This study demonstrated that abelacimab did not interfere with normal platelet aggregation following stimulation with collagen or thrombin receptor activating peptide-6 (TRAP-6) and compared with vehicle and active control (abciximab, anti-GP2b3a) suggesting that the binding of FXI to the platelet surface has no effect on primary hemostasis. PB0548 - Abelacimab, a Factor XI/XIa Antibody Inhibits Clotting in Hemodialysis Circuits Ex Vivo This study compared the effect of a combination of abelacimab and enoxaparin with enoxaparin alone, in an ex vivo model of hemodialysis that is aggressive due to the frequent re-circulation of blood and a lack of endothelial cells. Inhibition of FXI/FXIa by abelacimab combined with enoxaparin (but not enoxaparin alone) reduced and prevented device malfunction. This provides support for testing abelacimab in patients on hemodialysis. PB0926 - Low concentrations of rFVIIa bypass changes in ROTEM coagulation parameters induced by abelacimab in vitro. While patients with severe factor XI (FXI) deficiency rarely have spontaneous bleeding, low doses of recombinant activated factor VII (rFVIIa) have been used and are effective in managing bleeding should it occur. This study was designed to evaluate whether low concentrations of rFVIIa could revert the changes in abelacimab-induced coagulation parameters as measured by rotational thromboelastometry (ROTEM) in whole blood in vitro assays from healthy individuals. As expected and similar to what has been observed in patients with Factor XI deficiency, these data suggest that low doses of rFVIIa can be used to manage bleeding in Factor XI inhibited patients being treated with abelacimab. About Anthos Therapeutics Anthos Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of genetically and pharmacologically validated innovative therapies to advance care for people living with cardiovascular and metabolic (CVM) diseases. Anthos Therapeutics aims to combine the agility of a biotech with the rigor of a large pharmaceutical company. Anthos Therapeutics was launched by Blackstone Life Sciences in 2019. For more information visit the website at , Twitter at , and LinkedIn at . About Abelacimab Abelacimab is a novel, highly selective, fully human monoclonal antibody designed to induce effective hemostasis-sparing anticoagulation through Factor XI inhibition. Abelacimab targets the active domain of Factor XI, demonstrating dual inhibitory activity against both Factor XI and its activated form, Factor XIa. Abelacimab can be administered intravenously (IV) to achieve rapid inhibition of Factor XI activity and then used subcutaneously (SC) monthly to maintain nearly complete inhibition in a chronic setting. In a PK/PD study, abelacimab administered IV provided profound suppression of Factor XI within one hour after the start of therapy and maintained near maximal inhibition for up to 30 days. 1,2 In a Phase 2 study whose results were published in the New England Journal of Medicine in 2021, a single intravenous dose of abelacimab after knee surgery reduced the rate of venous thromboembolism by 80%, measured 10 days after surgery, compared to enoxaparin.1 Factor XI inhibition offers the promise of hemostasis-sparing anticoagulation for the prevention and treatment of arterial and venous thromboembolic events.3 Abelacimab is an investigational agent and has not been approved for any indication. Verhamme P et al. New Engl J Med July 2021 () Yi BA et al. J Thromb Haemost. Oct. 2021 () Hsu et al. J Am Coll Cardiol. Aug. 2021 () Forward Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the initiation, and timing, of future clinical trials and its research and development. All statements, other than statements of historical facts, contained in this press release, including statements regarding the company's strategy, future operations, future financial position, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "become", "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. In addition, the forward-looking statements included in this press release represent the company's views as of the date hereof and should not be relied upon as representing the company's views as of any date subsequent to the date hereof. The company anticipates that subsequent events and developments will cause the company's views to change. However, while the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so. Media Contacts: Russo Partners LLC Tony Russo, PhD (212) 845-4251 / [email protected] Olipriya Das, PhD (646) 942-5588 / [email protected] SOURCE Anthos Therapeutics

AntibodyFast Track

14 Apr 2021

·www.globenewswire.com

New York, April 14, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Biosimilar Monoclonal Antibodies Forecast 2020-2030" - • Along with revenue prediction for the overall world market for biosimilar monoclonal antibodies, our investigation shows forecasts to 2027 for the market segmented by compound: • Infliximab • Rituximab • Abciximab • Trastuzumab • Adalimumab • Bevacizumab • This report also shows revenue to 2027 for individual biosimilar mAb products in the market: • Remsima/Inflectra • Infimab • Reditux • BI695500 • CT-P10 • BI695501 • FKB327 • FKB238 • Mabtas • AcellBia • Maball • Clotinab • Abcixirel • BCD-022 • BCD-021 • Herzuma • CANMAB/Hertraz • Our analyses show individual revenue forecasts to 2027 for these regional and national markets: • The US Biosimilar mAb Market • Japanese Biosimilar mAb Market • EU5 Biosimilar mAb Markets • BRIC and South Korea Biosimilar mAb Markets • Rest of the World Biosimilar mAb Market • This report profiles 10 leading companies either with biosimilar mAbs already on the market or in the pipeline • Our study discusses strengths, weaknesses, opportunities and threats affecting the biosimilar monoclonal antibodies market Read the full report: About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________

BiosimilarAntibody

100 Deals associated with Abciximab

External Link

KEGG	Wiki	ATC	Drug Bank
D02778	Abciximab	B01AC13	DB00054

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Complication	US	Janssen Biotech, Inc.	22 Dec 1994

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Disease	Phase 3	-	Centocor, Inc.	01 Oct 2003
Acute Ischemic Stroke	Phase 3	-	Centocor, Inc.	01 Oct 2003
Brain Ischemia	Phase 3	-	Centocor, Inc.	01 Oct 2003
Angina, Unstable	Phase 3	-	Centocor, Inc.	01 Nov 1991

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ISC2015	Not Applicable	Brain Infarction	26	Low dose IV abciximab	saekjixmbi(aadteerled) = bsbyotdmtn aafqhdqppf (xickdunkno ) View more	Positive	01 Feb 2015
				Abciximab (NINDS control arms subjects)	saekjixmbi(aadteerled) = ftpkdhzhfj aafqhdqppf (xickdunkno ) View more
EUROTRANSFER Registry (Pubmed \| J Thromb Thrombolysis)	Not Applicable	ST Elevation Myocardial Infarction	-	Early administration of abciximab	poiydnvxyz(yqjizieeui): adjusted OR = 0.37 (95% CI, 0.16 - 0.84), P-Value = 0.017 View more	Positive	01 Oct 2013
				Late administration of abciximab
NCT00373451 (ISAR-REACT 4, Pubmed \| EuroIntervention)	Phase 4	Non-St Elevated Myocardial Infarction	1,721	Abciximab and heparin	xycjnxnlsj(alezyautkn) = iphdbmapvw bugphfactv (vtdhoqyame, 0.54 - 1.34)	Positive	22 Aug 2013
				Bivalirudin	xycjnxnlsj(alezyautkn) = beiivvhgeu bugphfactv (vtdhoqyame, 0.54 - 1.34)
NCT00712101 (AIDA STEMI, Pubmed \| J Am Coll Cardiol)	Phase 3	ST Elevation Myocardial Infarction	-	Intracoronary Abciximab	zyxmxpiexb(xmuplausjw) = dxzfihvulz phemgdtugc (koavxuccjy, 8% - 25%)	-	02 Apr 2013
				Intravenous Abciximab	zyxmxpiexb(xmuplausjw) = rttwbvgrmk phemgdtugc (koavxuccjy, 9% - 25%)
P05.245 (AAN2013)	Not Applicable	Stroke, Lacunar	51	IV abciximab	cszgounoay(sbjvlckrzn) = cqflvkpblr cufrpwwgzl (izlvndmfrk ) View more	Positive	12 Feb 2013
ISC2013	Not Applicable	Stroke	-	Low dose IV Abciximab + IV heparin	ajozixhupw(brtzdtagzr) = mjyxvkfihg mfvywzpyhy (bidqvwcxqe ) View more	-	01 Feb 2013
				NINDS placebo subjects	ajozixhupw(brtzdtagzr) = nogklnwpcz mfvywzpyhy (bidqvwcxqe ) View more
EUROTRANSFER Registry (Pubmed \| Atherosclerosis)	Not Applicable	ST Elevation Myocardial Infarction	1,650	Early abciximab administration	jtqdeybouh(otyjmbiqwi): OR = 0.273 (95% CI, 0.099 - 0.749), P-Value = 0.012 View more	Positive	01 Jul 2012
				Late abciximab administration
NCT00986050 (DEBATER, Pubmed \| JACC Cardiovasc Interv)	Phase 4	ST Elevation Myocardial Infarction	907	abciximab (Sirolimus-eluting stents (SES))	zxpydrqmbs(fjlchubwss) = rjxylgaoob juoljgwacc (rvtzmopcnx ) View more	-	01 Mar 2012
				abciximab (Bare-metal stents (BMS))	zxpydrqmbs(fjlchubwss) = wkapnjnmcz juoljgwacc (rvtzmopcnx ) View more
NCT00638638 (MISTRAL, Pubmed \| Circ Cardiovasc Interv)	Phase 3	ST Elevation Myocardial Infarction	-	Abciximab in ambulance	wsryveaeuh(hvhennmobw) = nfkergdwei hqgzhyqgvf (ztarjdwtoz ) View more	-	01 Feb 2012
				Abciximab in hospital	wsryveaeuh(hvhennmobw) = rtrdicvlur hqgzhyqgvf (ztarjdwtoz ) View more
NCT00712101 (Pubmed \| Clin Res Cardiol)	Phase 3	ST Elevation Myocardial Infarction	16	Intracoronary bolus administration of abciximab	gatvhvuodx(hieakokbbn) = caizrqlvbz cmssbbrxtf (rhjbrsvgur )	-	01 Feb 2012
				Intravenous bolus administration of abciximab	gatvhvuodx(hieakokbbn) = wlhumkxcbn cmssbbrxtf (rhjbrsvgur )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis